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Letters to the Editorimportant hints to our case and future
device applications. Regarding our
case, we explicitly asked the patient
for any known allergies at the time of
the operation and repeated this query
after the comment from Kounis and
colleagues. The patient denied any al-
lergies; however, a skin test for sensi-
tivity to nickel or other metals was
not performed. In addition, after initial
interventional Amplatzer PFO oc-
cluder implantation, the patient was
without any signs of discomfort, palpi-
tations, dyspnea, headache, pericardial
effusion, or conspicuously altered lab-
oratory values, the main symptoms
of Kounis hypersensitivity-associated
syndrome, for almost 33 months. The
symptom that precipitated readmission
to the hospital was a stroke, which
was most likely due to the thrombus
formation on the atrial disk of the
Amplatzer device. We cannot rule
out, the possibility that the Kounis
hypersensitivity-associated syndrome
played some role in development of
this thrombus formation; however,
the histologic examination of the ex-
planted device and thrombus did not
reveal any inflammatory cells. In
a multicenter-study of PFO closure
device explants, the rate of explants
was 0.28%.3 Most of these explants
were due to persistent or unknown
chest pain, and half of these patients
had a known nickel allergy. In addition
it is shown, that in patients with known
nickel allergy the rate of chest discom-
fort and palpitations is significantly
increased after PFO device closure.4
None of these signs were found in
our patient.
We fully agree with Kounis and col-
leagues that a possible nickel allergy
should be ruled out before elective im-
plantation of intracardiac metal de-
vices. Otherwise, the patient should
be made aware of the possibility of
device explantation when informed
consent is obtained.
Stefan Klotz, MD
Department of Cardiac and Thoracic
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ULTRASOUND–GUIDED
MEDIASTINAL LYMPH NODE
NEEDLE ASPIRATION IN
NON–SMALL CELL LUNG
CANCER: FROM THEORY TO
PRACTICE
To the Editor:
We read with pleasure the article by
Lee and colleagues.1 Endobronchial
ultrasound-guided transbronchial nee-
dle aspiration (EBUS-TBNA) is a new
diagnostic technique that provides
a minimally invasive option for medi-
astinal staging in patients with lung
cancer. This technique was described
by Krasnik and colleagues2 in 2003
and rapidly gained the interest of the
scientific community. Nonrandomized
studies demonstrate that EBUS-TBNA
affords excellent diagnostic perfor-
mance with a sensitivity ranging from
70% to 99% and a negative predictive
value up to 98%.3 Those excellent pre-
liminary results convinced the Ameri-
can College of Chest Physicians to
advocate EBUS-TBNA to stage the
mediastinum only 4 years after the first
description of the technique.
In 2006, we had the opportunity to
use the first dedicated bronchoscope
imported to Italy, and the potential
of EBUS-TBNA was immediately
obvious. The short learning curve,of Thoracic and Cardiovascular Surgehigh diagnostic accuracy, minimal
invasiveness, and possible surgical
sparing encouraged us to use EBUS-
TBNA even outside of lung cancer
staging.4
In a paradoxical way, the excellence
of the preliminary results delayed the
production of randomized studies, and
to date only Annema and colleagues,5
pioneers in endobronchial ultrasound,
published the randomized clinical trial,
ASTER (Assessment of Surgical Stag-
ing Versus Endosonographic Ultra-
sound in Lung Cancer). In the aseptic
world of scientific trials, the report by
Lee and colleagues1 attracts our atten-
tion for its ability to focus interest on
clinical practice. The brilliant results
reported by the authors demonstrate
the high diagnostic value of EBUS-
TBNA and the undoubtable skill of
the operators. We do recommend rapid
on-site evaluation of the specimen be-
cause it can decrease the rate of inade-
quate tests.
Reports with strong clinical charac-
teristics, as well as randomized trials,
are needed to validate EBUS-TBNA,
especially for its potential capability
of avoiding unnecessary surgery.
Mario Nosotti, MD
Matilde De Simone, MD, PhD
Ugo Cioffi, MD, PhD
Department of Surgery
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Maggiore Policlinico
University of Milan
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We thank Drs Nosotti, Simone, and
Cioffi for their kind remarks and excel-
lent commentary regarding our recent
publication.1 Endobronchial ultrasound-
guided transbronchial needle aspiration
(EBUS-TBNA) is truly an emerging
technology that allows safe and accu-
rate assessment of the mediastinum
in patients with non–small cell lung
cancer. We also anticipate the results
of the ASTER trial2 with hopes that it
will further validate our findings.
We also understand the valid point
made regarding the utility of rapid on-
site evaluation during EBUS-TBNA.
To this end, recent studies have sought
to investigate the utility of rapid on-site
evaluation.3,4 However, in a practical
sense, it may not always be possible
to have access to the service of an
experienced cytopathologist at all
times during the performance of
EBUS-TBNA. Practice patterns ulti-
mately are developed with the re-
sources that are available within
a given institution.
Altogether, EBUS-TBNA provides
a safe and reliable method of assessing
the mediastinum in patients with non–
small cell lung cancer. Whether the
results are available instantaneously or
in a couple of days, what matters the
most is achieving an accurate result.
Benjamin E. Lee, MD
Robert J. Korst, MD
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Department of Surgery
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USINGCLOPIDOGREL BEFORE
CORONARYARTERY BYPASS
SURGERY: A ROLE OF
PLATELET FUNCTION
ASSESSMENT
To the Editor:
We read with great interest the re-
cently published systematic review
and meta-analysis of randomized trials
and observational studies by Biancari
and colleagues.1 When assessing the
influence of preoperative antiplatelet
therapy (APT) administration manage-
ment on bleeding and adverse ischemic
events, the objective quantification of
platelet activity should inextricably be
included in the considerations. Ex-
pected inhibition of platelet function
is not always achieved after APT
administration. The frequency of low
responsiveness to aspirin and clopidog-
rel has been reported to range from 1%
to 45% for the 2 drugs.2 The efficacy of
platelet inhibition with aspirin and clo-
pidogrel varies widely among patients,
from intensive platelet inhibition to
poor platelet response. The effect of
clopidogrel on bleeding mainly de-
pends on2 factors: (1) observedplatelet
inhibition, which depends on inherent
platelet activity before clopidogrel
administration and platelet inhibitory
response to clopidogrel, and (2) the
ability of newborn platelets to restore
normal aggregation after clopidogrelardiovascular Surgery c July 2012discontinuation. This results in individ-
ual widespread variability in the activ-
ity of adenosine diphosphate platelet
receptors, which consequently reflects
similar variability in proclivity to ex-
cessive bleeding or adverse ischemic
events. Awidi and colleagues3 found
that the combination of aspirin and
clopidogrel had greater inhibitory
effects on platelet aggregation than ei-
ther agent alone. There is evidence
that certain patients have an accentu-
ated response to the usual doses of pre-
operative aspirin that may result in
increased perioperative blood loss.4
Therefore, the benefits and risks of us-
ing clopidogrel before coronary artery
bypass grafting (CABG) should be in-
dividually assessed according to plate-
let function tests, and the role of
aspirin should inevitably be included
in the considerations. For patients re-
ceiving dual APT (aspirinþ clopidog-
rel) before CABG, the influence of
aspirin on bleeding and ischemic ad-
verse events should be examined sepa-
rately using anaspirin-sensitive platelet
function test. The role of aspirin and
clopidogrel should be assessed sepa-
rately by drug-specific platelet func-
tion tests to provide the most precise
and reliable information on the benefits
and risks of preoperative administra-
tion for each antiplatelet agent, thus
facilitating an individual approach to
patients with the aim of reducing
bleeding and adverse ischemic events.
Evaluation of the effect ofAPT (aspirin
or clopidogrel) on both bleeding and is-
chemic events should be based on
platelet function assessment with sub-
sequent distinction of patients with
high residual platelet activity, thus
a proclivity to ischemic events, or
enhanced platelet inhibition, thus a pro-
clivity to excessive bleeding. Thegroup
of patients with pronounced platelet in-
hibition observed during APT could
benefit from early preoperative APT
withdrawal in terms of excessive bleed-
ing prevention. For patients undergoing
CABG, individually tailored APT ad-
ministration management based on
platelet function tests, both pre- and
